Kemira: the price-cost gap is winning
A bought-growth quarter, a 9.3% packaging margin, and a price-pass-through story that keeps getting pushed to next quarter
KEMIRA.HE · Earnings Call · 2026-10-23
The headline: growth bought, margins lost
Kemira's Q3 2026 report is not a demand recovery story. Revenue rose by just over EUR 20 million, but acquisitions supplied EUR 18 million of that; “Sales volumes decreased year-on-year while organic growth was flat.” — Tuomas Mäkipeska, Chief Financial Officer · 2026-10-23 Operative EBITDA fell to EUR 113 million, a 15.9% margin, and earnings per share were EUR 0.21. The CEO did not soften it: “the profitability was a clear disappointment for us. Operative EBITDA declined to below 16%, and that happened in all the business units.” — Antti Salminen, President and CEO · 2026-10-23 The cause is the same cost-price squeeze that has dominated the last several quarters: the Middle East conflict lifted raw material, energy and logistics costs, and Kemira — a downstream chemicals producer — gets the full hit without the upstream uplift. Management still sizes the gross 2026 hit at roughly EUR 100 million and still assumes about half can be mitigated, but the mitigation is uneven. What changed this quarter is not the existence of the squeeze; it is the evidence that the squeeze is outrunning the response. Sales prices rose, and customer price increases began to bite late in the quarter, but not enough. Fixed cost cuts contributed EUR 8 million, but raw material inflation alone was a EUR 35 million drag. The demand environment is weak and, in management's words, shows no sign of significant improvement.The PHS credibility gap
The sharpest number in the release is the Hygiene Solutions margin: 9.3% operative EBITDA in Packaging & Hygiene Solutions. Antti Salminen called it 'a really bad quarter in terms of profitability' and then explained why the business is the weakest link:This is where the historical record matters. A year ago, on the Q3 2025 call, the message was that the PHS fix would take time:the Packaging & Hygiene Solutions got really the most severe and maybe kind of bigger than expected hit from the raw materials. Then again, there the end market was the softest, so also our capability to pass through the cost increases was the weakest.
By the Q4 2025 call, the ambition was still a mid-teens margin by the end of 2026. Joni Sandvall of Nordea asked whether the 15% target was still valid; Antti Salminen answered: “whether the market support reaching that exactly during the last quarter of '26 or later in '27, that depends, but that's the ambition level that we have set for.” — Antti Salminen, President and CEO · 2026-02-12 Nine months later, PHS is at 9.3%, not mid-teens. The old operating-model change is visible in lower fixed costs, but it is not enough to offset raw materials in a soft packaging market. That is the credibility gap: the target has not been formally abandoned, but the runway has been extended again. The pricing mechanism was supposed to close the gap. In the Q2 2026 call, management said the lag was up to two quarters and that Q4 would show the full impact of the price actions taken earlier: “the delay typically is up to two quarters, basically you would see the full impact of the price increase actions done now in quarter four.” — Antti Salminen, CEO · 2026-07-17 Q4 is now here, and the message is more conditional. PHS price increases are still being pushed, but the customer end markets are too weak to accept them quickly. The new formula based pricing language in the Q&A — monthly or quarterly pass-through in some contracts, freely negotiated deals in others — is a reminder that Kemira does not have a single lever it can pull.the profit improvement need is not over in PHS business unit at all... this will actually take, like I said, well into next year as we are implementing it.